Takeda divests more non-core products for $660 million

5 November 2019

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) today revealed a new agreement to divest a portfolio of select products to Germany’s Stada Arzneimittel (SAZ: Xetra) for a total value of $660 million.

The portfolio includes over-the-counter (OTC) and prescription pharmaceutical products exclusively in Russia, Georgia, and a number of countries from within the Commonwealth of Independent States (CIS), where Stada has considerable marketing strength, and which form part of Takeda’s Growth & Emerging Markets Business Unit.

This is Takeda’s fourth divestment transaction in the past six months that contributes to the company’s goal to divest approximately $10 billion in non-core assets to focus on its five key business areas and commitment to accelerating its deleveraging following its acquisition of Shire.

Divestments to Novartis, Ethicon and Acino

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK